Spero Therapeutics Inc
Research Spero Therapeutics Inc (SPRO) on Bullrun: valuation model: 31.6% undervalued, market cap USD 130.86M, P/E 9.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal31.6% undervalued
- Market capUSD 130.86M
- P/E9.3
- Financial periodFY2025
- RevenueUSD 12.59M
- Revenue growth3292.5%
- Net incomeUSD 8.57M
Valuation Snapshot
Bullrun's latest valuation model marks Spero Therapeutics Inc as 31.6% undervalued; latest market cap is USD 130.86M; P/E is 9.3.
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Frequently asked questions
Is Spero Therapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Spero Therapeutics Inc as 31.6% undervalued.
What is Spero Therapeutics Inc's market cap?
Spero Therapeutics Inc's market capitalization is USD 130.86M.
What is Spero Therapeutics Inc's P/E ratio?
Spero Therapeutics Inc's price-to-earnings (P/E) ratio is 9.3.
What does Spero Therapeutics Inc do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.